Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer

Conditions

• Esophageal Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• cisplatin — DRUG
• fluorouracil — DRUG
• irinotecan hydrochloride — DRUG
• leucovorin calcium — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, irinotecan, leucovorin, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one chemotherapy drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy as first-line therapy works in treating patients with metastatic esophageal cancer.

Key Dates

Start date

Oct 31, 2003

Status verified

Jul 2007

Study Design

Primary purpose

TREATMENT

Primary Outcome Measure

Objective response rate

Related Studies

• Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Esophageal Cancer Risk Registry
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
  Recruiting · University of Colorado, Denver · Aurora, Colorado